PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression

被引:32
作者
Citro, Simona [1 ]
Miccolo, Claudia [1 ]
Meloni, Laura [1 ]
Chiocca, Susanna [1 ]
机构
[1] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy
关键词
breast cancer; estrogen receptor; HDAC1/mTOR/PI3K/S6K1; HISTONE DEACETYLASES; GENE-EXPRESSION; SODIUM-BUTYRATE; S6; KINASE; C-MYC; ALPHA; PROTEIN; ACTIVATION; TRANSCRIPTION; INHIBITION;
D O I
10.1093/jmcb/mjv021
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Histone deacetylase 1(HDAC1) is an important epigenetic controller involved in transcriptional regulation through modification of chromatin structure. Genetic and epigenetic changes and deregulation of signal transduction pathways have been implicated in the development of breast cancer. Downregulation of estrogen receptor alpha (ER alpha) expression is one of the mechanisms behind the acquisition of endocrine resistance. Sustained and increased hormone and growth factor receptor signaling in breast cancer cells contribute to resistance to endocrine therapy. Both HDACs and the PI3K/mTOR signaling pathway are becoming promising targets in breast cancer, reversing also acquired hormone resistance. Here we show how mitogens, activating the PI3K/mTOR pathway, trigger the phosphorylation of HDAC1 in breast cancer cells, which is completely dependent on the activity of the p70 S6 kinase (S6K1). Our findings show that S6K1, overexpressed in many breast cancers, controls HDAC1-dependent transcriptional regulation of ER alpha levels upon mitogenic stimuli, controlling HDAC1 recruitment to the ER alpha promoter. Furthermore, cell treatment with both mTOR and HDACs inhibitors shows an additive effect in inhibiting breast cancer proliferation. This confirms the novel cross-talk between the HDAC1 and PI3K pathways with clinical implications towards the treatment of this malignant disease.
引用
收藏
页码:132 / 142
页数:11
相关论文
共 42 条
[1]   Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis [J].
Bärlund, M ;
Forozan, F ;
Kononen, J ;
Bubendorf, L ;
Chen, YD ;
Bittner, ML ;
Torhorst, J ;
Haas, P ;
Bucher, C ;
Sauter, G ;
Kallioniemi, OP ;
Kallioniemi, A .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) :1252-1259
[2]   GLUCOCORTICOID RECEPTOR-DEPENDENT DISRUPTION OF A SPECIFIC NUCLEOSOME ON THE MOUSE MAMMARY-TUMOR VIRUS PROMOTER IS PREVENTED BY SODIUM-BUTYRATE [J].
BRESNICK, EH ;
JOHN, S ;
BERARD, DS ;
LEFEBVRE, P ;
HAGER, GL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (10) :3977-3981
[3]   Mammalian histone deacetylase 1 protein is posttranslationally modified by phosphorylation [J].
Cai, R ;
Kwon, P ;
Yan-Neale, Y ;
Sambuccetti, L ;
Fischer, D ;
Cohen, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 283 (02) :445-453
[4]   Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells [J].
Chang, Sharon B. ;
Miron, Penelope ;
Miron, Alexander ;
Iglehart, J. Dirk .
JOURNAL OF SURGICAL RESEARCH, 2007, 138 (01) :37-44
[5]   A role for paralog-specific sumoylation in histone deacetylase 1 stability [J].
Citro, Simona ;
Jaffray, Ellis ;
Hay, Ronald T. ;
Seiser, Christian ;
Chiocca, Susanna .
JOURNAL OF MOLECULAR CELL BIOLOGY, 2013, 5 (06) :416-427
[6]   Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER plus breast cancer [J].
Creighton, Chad J. ;
Fu, Xiaoyong ;
Hennessy, Bryan T. ;
Casa, Angelo J. ;
Zhang, Yiqun ;
Gonzalez-Angulo, Ana Maria ;
Lluch, Ana ;
Gray, Joe W. ;
Brown, Powell H. ;
Hilsenbeck, Susan G. ;
Osborne, C. Kent ;
Mills, Gordon B. ;
Lee, Adrian V. ;
Schiff, Rachel .
BREAST CANCER RESEARCH, 2010, 12 (03)
[7]   The effects of sodium butyrate on transcription are mediated through activation of a protein phosphatase [J].
Cuisset, L ;
Tichonicky, L ;
Jaffray, P ;
Delpech, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (39) :24148-24153
[8]   Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity [J].
DeGraffenried, LA ;
Friedrichs, WE ;
Russell, DH ;
Donzis, EJ ;
Middleton, AK ;
Silva, JM ;
Roth, RA ;
Hidalgo, M .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :8059-8067
[9]   The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer [J].
Dillon, R. L. ;
White, D. E. ;
Muller, W. J. .
ONCOGENE, 2007, 26 (09) :1338-1345
[10]   ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors [J].
Duong, V ;
Licznar, A ;
Margueron, R ;
Boulle, N ;
Busson, M ;
Lacroix, M ;
Katzenellenbogen, BS ;
Cavaillès, V ;
Lazennec, G .
ONCOGENE, 2006, 25 (12) :1799-1806